



MANAGEMENT of RAISED INTRACRANIAL **PRESSURE**

Please also refer to the related WPD

Raised intra-cranial pressure (ICP) is associated with worse symptoms, including: headache, nausea, diplopia secondary to sixth cranial nerve palsies, and altered mental status.

Repeated daily therapeutic lumbar punctures (LP) are sufficient to control raised pressure in the majority of patients.

Identify CSF opening pressure (OP) at baseline LP

A prompt baseline lumbar puncture is strongly encouraged,

but in the presence of **focal neurologic signs**, excluding sixth (VIth) cranial nerve palsies, it should be delayed pending the results of a computed tomography (CT) or magnetic resonance imaging (MRI) scan, if available.



If CSF **OP** is \geq 30 cm H₂0, remove **CSF** (therapeutic LP)

If OP 20-30, therapeutic LPs are at the discretion of the study doctor who will be guided by patient symptoms

Reduce OP by 50% if OP very high or to a normal pressure of < 20 cm H₂0

Do not remove more than 40 ml of CSF at any therapeutic LP

The CSF OP should be rechecked after removal of every 10mL CSF.



If the preceding day, OP was ≥ 30 cm H₂O, repeat daily LP to evaluate OP If OP was 20-30, therapeutic LPs guided by symptoms and signs of raised ICP

Perform daily therapeutic LP until the <u>CSF pressure and symptoms</u> have been stabilized for > 2 days



Consider temporary percutaneous lumbar drains or ventriculostomy, if over 14 daily LPs required to control OP

NB This requires significant monitoring and is an infection risk, therefore should only be contemplated if sufficient resources are available for managing a lumbar drain

Patients admitted to the study, regardless of their initial opening pressure. will undergo serial lumbar punctures on days 1, 7 and 14 of their admission. The opening pressure must be measured and documented for each and every lumbar puncture.

Mannitol has no proven benefit and is not recommended. Acetazolamide should be avoided to control increased intracranial pressure. Corticosteroids should not routinely be used during induction therapy for HIV-associated cryptococcal meningitis.











